在阿尔茨海默氏症疾病中INPP5D的病理作用
Yung Ning Chu1, Aika Akahori1, Sho Takatori1
1Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Advances in experimental medicine and biology
|July 31, 2023
概括
伊诺西聚酸-5-多酸酶D (INPP5D) 负面调节粉样斑块周围的微质聚类,这是阿尔茨海默病 (AD) 发病的一个关键过程. 了解INPP5D的作用可能会揭示AD的新治疗点.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默氏病 (AD) 的发病包括粉样β (Aβ) 沉积和病理,导致认知能力下降.
- 遗传联系表明微质,特别是通过TREM2 (在骨髓细胞2上表达的触发受体),在AD中发挥关键作用.
- TREM2促进了粉样斑块周围的微质聚类,形成了对Aβ毒性的保护屏障,并影响了tau沉积.
研究的目的:
- 审查伊诺西多-5-酸酶D (INPP5D) 的作用,这是一个AD风险基因,在微中表达.
- 探索INPP5D与粉样斑块的微质反应及其与TREM2信号交互的功能.
- 确定INPP5D作为阿尔茨海默病的潜在治疗点.
主要方法:
- 关于INPP5D在AD中的生理和病理作用的研究文献综述.
- 分析证据,将INPP5D风险多态性与改变的基因表达和tau水平联系起来.
- 检查INPP5D对β-氨基粉症小鼠模型中的微质聚类的影响.
主要成果:
- 在小鼠模型中,INPP5D因Aβ沉积而受到上调.
- INPP5D负面调节了粉样斑块周围微质的聚类.
- INPP5D似乎对TREM2信号产生敌对作用,调节微质保护屏障.
结论:
- 在阿尔茨海默病的背景下,INPP5D是微质功能的一个新型调节器.
- 它对TREM2的对抗作用表明在AD病变发生过程中存在复杂的相互作用.
- 对INPP5D的进一步研究可能会导致阿尔茨海默病的新治疗策略.
关键词:
阿尔茨海默氏症 (AD) 是一种疾病.粉样蛋白的假设粉样蛋白β (Aβ) 是一种遗传风险因素是一种遗传风险因素.伊诺西多酸-5-多酸酶D (INPP5D) 的使用微质细胞中的微质细胞酸的含量是多少 酸的含量是多少塔乌·塔乌 (Tau Tau) 是一个在骨髓细胞2 (TREM2) 上表达的触发受体 (TREM2)更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
09:52Modified Roller Tube Method for Precisely Localized and Repetitive Intermittent Imaging During Long-term Culture of Brain Slices in an Enclosed System
Published on: December 28, 2017
10.7K
相关概念视频
Alzheimer's Disease: Overview
522
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
522
Alzheimer's Disease: Treatment
218
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
218
